## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 10/650,559 Confirmation No: 1600 Filed: 08/28/2003 Art Unit: 1645

Applicant:

Jeffrey ENGLER Brian GANGLE

Examiner: Brian GANGLE Attorney Docket No: P66186US01GP

Title: Group B Streptococcal phage lysin

## APPLICANT'S INTERVIEW SUMMARY

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Sir/Madam:

This paper serves as the Applicant's interview summary as required under 37 C.F.R. § 1.133(b) as further explained in MPEP § 714.04. A telephonic interview was conducted between Examiner Gangle and Applicant's attorney Landau on 27 March 2009. The patentability of Claims 49-55 with regard to the requirements of 35 U.S.C. § 112 was discussed. Applicant and Examiner agreed that the claims will meet the requirements of 35 U.S.C. § 112 if amended to recite glycosidase activity, bacteriolytic activity, a certain degree of homology, or any of these characteristics in combination.

Reconsideration is respectfully requested. If the Examiner requires additional action that may benefit from a telephone call, Applicants invite a call to its attorney of record, Nicholas J. Landau (Reg. No. 57,120) at (205) 521-8545. E-mail correspondence and transactions to nlandau@babc.com are authorized and encouraged. The Application

3/27/2009 Date Attorney Docket No: P66186US01GP

is believed to be in condition for allowance, and a timely Notice of Allowance is respectfully requested.

Respectfully submitted,

BRADLEY ARANT BOULT CUMMINGS LLP

Nicholas J. Landau

Reg. No. 57,120